Epigenetic regulation of Alzheimer s disease related genes
Alzheimer’s disease (AD) and other dementias affect over 7 million individuals in Europe. There is, as yet, no treatment to halt or reverse disease progression despite huge investments into research. The accumulation of the amyloi...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PID2019-111240RA-I00
ALTERACIONES DE LA ENFERMEDAD DE ALZHEIMER CAUSADAS POR LA A...
155K€
Cerrado
SAF2016-80419-R
REGULACION DE LA MULTIPOTENCIALIDAD DE CELULAS MADRE NEURALE...
157K€
Cerrado
NEVULA
Understanding selective neuronal vulnerability in Alzheimer...
247K€
Cerrado
MIRNA_AD
Role of microRNA dysregulation in Alzheimers Disease
3M€
Cerrado
PRE2020-094049
ROL DE LA POLYADENILACION ALTERNATIVA EN LA DIFERENCIACION N...
99K€
Cerrado
CTS-TEs-ADprogress
Cell type specific molecular analysis of epigenetic changes...
175K€
Cerrado
Información proyecto EpiRegAD
Líder del proyecto
UNIVERSITY OF LEEDS
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
101K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Alzheimer’s disease (AD) and other dementias affect over 7 million individuals in Europe. There is, as yet, no treatment to halt or reverse disease progression despite huge investments into research. The accumulation of the amyloid beta-peptide (Abeta), derived from the amyloid precursor protein (APP) in the brain, is a key factor in the development of AD but the roles of other APP metabolites are poorly understood. This project will focus on one of these metabolites, its intracellular domain, AICD, and the mechanism for its nuclear trafficking and gene transcriptional regulation, especially of the Abeta-degrading enzyme, neprilysin (NEP), which maintains Abeta homeostasis. These studies will focus on the differential contributions of the three APP isoforms to AICD production, nuclear trafficking and gene regulation, and will use a variety of neuronal and non-neuronal models to analyse epigenetic changes mediating NEP expression including chromatin composition of the NEP gene in active and downregulated states and whether APP isoform effects are direct or indirect. In parallel, other putative AICD-responsive genes will be compared (aquaporin, GSK-3beta). This will allow us to formulate strategies for up-regulation of key neuroprotective genes in disease leading to potential new therapeutic approaches. The project will provide the Research Fellow with broad experience in molecular neuroscience (from bioimaging and protein trafficking to chromatin analysis and gene regulation) in a well-founded, integrated and multi-disciplinary environment for AD research.